Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis

Abstract

AbstractBackgroundCytomegalovirus (CMV) is associated with morbidity and mortality in solid organ transplant recipients (SOTR). Valganciclovir (VGC) is extensively used for prophylaxis. Optimal dosing in children, risk factors for failure, and the impact of dose adjustments on CMV DNAemia is not well established.MethodsThis retrospective cohort study of pediatric SOTR transplanted between 2010–2018 evaluated the epidemiology of CMV DNAemia and used Cox‐regression to assess the risk factors for CMV DNAemia within one‐year following SOTR.ResultsIn 393 pediatric SOTR (heart [96, 24.4%], kidney [180, 45.6%], liver [117, 29.8%]; median age 9.5 ± 0.3 years), overall CMV DNAemia incidence was 6.6/10 000 days (95%CI 5.1/10 000–7.9/10 000) and varied by organ groups: heart 8.2/10 000 days (95%CI 4.9/10 000–11.4/10 000), kidney 5.8/10 000 days (95%CI 3.9/10 000–7.8/10 000), liver 6.2/10 000 days (95%CI 3.7/10 000–8.7/10 000). CMV DNAemia was detected in 75 of 275 (27.2%) patients who received prophylaxis (40 cases occurred during prophylaxis and 35 occurred after completion of prophylaxis). The median VGC dose given according to institutional weight‐based algorithm was approximately 1.5‐fold lower than the manufacturer‐recommended dose. This discordance was more prominent at younger age groups (3.2‐fold lower in <2‐year‐old [100 mg versus 325 mg], 2.5‐fold lower in <6‐year‐old [200 mg versus 447 mg]). Dose reduction due to adverse events was an independent risk factor for breakthrough CMV DNAemia (hazard ratio 2.2, 95%CI 1.2–3.8) among patients with similar age, CMV risk stratification, starting VGC dose, immunosuppressive therapy, and organ group.ConclusionCMV events occurred while on VGC prophylaxis. Weight‐based VGC may prevent supratherapeutic VGC exposure especially in younger children. Dose reduction of VGC prophylaxis for adverse event management places patients at an increased risk for CMV DNAemia suggesting other agents with fewer adverse effects should be considered and need to be studied in children.